Skip to content

Studying the effects of anticoagulation colchicine on sepsis patients

Investigating the platelet stabilization and anticoagulants of Colchicine in septic patients admitted to intensive care unit

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250501065550N1
Enrollment
50
Registered
2025-06-21
Start date
2025-06-22
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis. Other sepsis

Interventions

Intervention 1: Intervention group: Colchicine: In addition to standard treatment, this group of patients will receive 1 mg of colchicine orally every 12 hours for 5 days (25 patients). Intervention 2

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Septic patients admitted to the ICU (diagnosed according to Sepsis-3 criteria) Age over 18 years Providing written informed consent Having conditions for enteral nutrition

Exclusion criteria

Exclusion criteria: Pregnant women Individuals with very low body weight (body mass index (BMI) <18.5 kg/m2) Patients requiring frequent blood transfusions Patients with septic shock and those patients who experience unwanted side effects after taking the supplement or placebo will be excluded from the study

Design outcomes

Primary

MeasureTime frame
SOFA Score. Timepoint: Day 1 and Day 5. Method of measurement: Clinical and laboratory parameters including PaO2/FiO2 ratio, platelet count, bilirubin, mean arterial pressure, Glasgow Coma Scale, creatinine, and urine output.;D-dimer. Timepoint: Day 1 and Day 5. Method of measurement: Quantitative immunoassay in plasma via Enzyme-linked immunosorbent assay (ELISA).;Fibrinogen. Timepoint: Day 1 and Day 5. Method of measurement: Immunoturbidimetric assay on clinical chemistry analyzers.;PAI_1. Timepoint: Day 1 and Day 5. Method of measurement: Sandwich ELISA assay.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Kiumarth Amini

Hamedan University of Medical Sciences

K_amini@umsha.ac.ir009125197344

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026